List of Excipients in Branded Drug MYDCOMBI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eyenovia Inc	MYDCOMBI	tropicamide and phenylephrine hydrochloride	81046-0111	BENZALKONIUM CHLORIDE	2026-05-05
Eyenovia Inc	MYDCOMBI	tropicamide and phenylephrine hydrochloride	81046-0111	HYDROCHLORIC ACID	2026-05-05
Eyenovia Inc	MYDCOMBI	tropicamide and phenylephrine hydrochloride	81046-0111	SODIUM HYDROXIDE	2026-05-05

Mydcombi Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Mydcombi is a fixed-dose ophthalmic spray containing tropicamide 1% and phenylephrine hydrochloride 2.5%. Its commercial differentiation depends less on new pharmacology than on delivery efficiency, dose consistency, preservative strategy, packaging, and clinical workflow. The principal opportunity is to replace separate dilating drops with a metered, lower-volume administration system for ophthalmology practices, optometry offices, and ambulatory procedures.

What is Mydcombi and how does its formulation work?

Mydcombi is FDA-approved for producing mydriasis, or pupil dilation, for diagnostic procedures. Eyenovia developed the product using its Optejet dispensing platform, which delivers a metered ophthalmic spray onto the eye surface rather than relying on conventional drop administration (U.S. Food and Drug Administration [FDA], 2023a).

Attribute	Mydcombi
Active ingredients	Tropicamide 1%; phenylephrine hydrochloride 2.5%
Therapeutic use	Induction of mydriasis for ophthalmic examination
Dosage form	Metered ophthalmic spray
Regulatory status	FDA-approved in 2023
Sponsor	Eyenovia, Inc.
Pharmacologic components	Anticholinergic plus sympathomimetic
Primary commercial setting	Eye-care offices, diagnostic clinics, and procedural settings
Core differentiation	Fixed-dose combination and spray-based administration

Tropicamide blocks muscarinic receptors in the iris sphincter muscle. Phenylephrine stimulates alpha-adrenergic receptors in the iris dilator muscle. The combination produces dilation through complementary mechanisms and is intended to simplify administration compared with separate products.

The formulation challenge is to maintain chemical stability, sterility, spray performance, ocular tolerability, and dose reproducibility while limiting the volume delivered to the eye.

What excipients are used in Mydcombi?

The Mydcombi prescribing information identifies a conventional ophthalmic excipient system consisting of buffering and tonicity agents, water, and pH adjusters. The inactive ingredients include boric acid, sodium borate decahydrate, sodium chloride, hydrochloric acid and/or sodium hydroxide, and purified water (FDA, 2023b).

Excipient or component	Likely formulation function	Strategic relevance
Boric acid	Buffering and pH control	Supports ocular tolerability and chemical stability
Sodium borate decahydrate	Buffering capacity	Helps maintain pH during shelf life
Sodium chloride	Tonicity adjustment	Reduces ocular discomfort from hypotonic or hypertonic delivery
Hydrochloric acid and/or sodium hydroxide	Final pH adjustment	Provides manufacturing control over pH specification
Purified water	Vehicle	Must meet pharmaceutical water quality requirements
Container-closure system	Dose metering and sterility protection	Central to product performance and intellectual-property value

The absence of a conventional antimicrobial preservative is commercially relevant if confirmed for the marketed presentation. A preservative-free or preservative-minimized design can reduce concerns about ocular surface toxicity, particularly in patients undergoing repeated examinations or procedures. It also shifts product-development risk toward container-closure integrity, aseptic manufacturing, and in-use microbial control.

Why is the excipient strategy commercially important?

The excipient system supports four commercial objectives:

1. Ocular tolerability. Borate buffering and sodium chloride help control pH and tonicity, which can affect burning, stinging, tearing, and patient acceptance.
2. Compatibility with the spray device. Low viscosity and controlled solids content are important for consistent atomization and prevention of nozzle blockage.
3. Chemical stability. Tropicamide and phenylephrine must remain within potency and impurity specifications through the labeled shelf life.
4. Manufacturing reproducibility. A simple aqueous system can reduce formulation complexity, but the delivery device becomes a critical process parameter.

The commercial value of the excipient system is therefore linked to the device. An equivalent active-ingredient formulation delivered through a conventional dropper may not reproduce the same dose profile, ocular distribution, or workflow benefits.

What formulation attributes create a competitive advantage?

Metered low-volume delivery

Conventional eye drops often deliver a volume exceeding the eye’s tear-film capacity. Excess liquid can spill onto the eyelid or drain through the nasolacrimal duct, increasing systemic exposure and reducing dose efficiency. A metered spray can reduce variability caused by drop size, bottle angle, blinking, and operator technique.

The value proposition is strongest when the product demonstrates:

• Consistent delivered dose across the labeled life of the device
• Reliable spray plume formation
• Low residual volume
• Minimal dependence on bottle orientation
• Limited runoff and facial exposure
• Repeatable performance across temperature and humidity ranges

Preservative-free positioning

Preservative-free ophthalmic products have an established commercial rationale in patients with ocular surface disease, contact-lens-related sensitivity, or frequent exposure to topical products. For Mydcombi, this positioning may support adoption in high-volume practices that perform repeated examinations.

The tradeoff is manufacturing and packaging complexity. Preservative-free products need robust aseptic controls or a validated multidose system that restricts microbial ingress. The device must also prevent contamination during repeated use.

Buffer and tonicity optimization

Buffer selection affects more than pH. It can influence:

• Active-ingredient solubility
• Degradation rate
• Ocular comfort
• Corneal exposure
• Device-material compatibility
• Extractables and leachables profile

A borate-based system is familiar in ophthalmic formulations, but commercial development should assess borate concentration, buffer capacity, and pH drift after filling and during storage. Excessive buffer capacity can make the formulation less adaptable to the ocular surface, while inadequate capacity can permit pH movement during shelf life.

What formulation patents and intellectual-property barriers protect Mydcombi?

Mydcombi’s defensibility is likely to depend on a combination of formulation, device, method-of-use, and manufacturing rights rather than on the active ingredients themselves. Tropicamide and phenylephrine are established compounds with limited composition-of-matter exclusivity value for this product.

IP category	Potential protection	Commercial impact
Device patents	Metered spray mechanism, nozzle, actuator, dose chamber	May restrict direct device substitution
Formulation patents	Concentration ranges, pH, tonicity, excipient combinations	May complicate formulation design-around
Combination patents	Fixed-dose tropicamide and phenylephrine presentations	Supports product-specific protection
Method-of-use patents	Spray administration for diagnostic mydriasis	May affect label-based competition
Manufacturing patents	Filling, priming, dose calibration, aseptic assembly	Can raise scale-up and supply-chain barriers
Trade secrets	Device calibration, plume specifications, process controls	May delay replication without creating public patent barriers

The strongest practical barrier may be the interaction between the formulation and dispensing platform. A competitor could copy the active concentrations yet fail to match spray uniformity, sterility assurance, priming behavior, or delivered-dose performance.

What is the Orange Book status of Mydcombi?

Mydcombi is an FDA-approved prescription product listed in FDA drug databases. Patent and exclusivity diligence should distinguish among:

• FDA regulatory exclusivity
• Orange Book-listed patents
• Device patents
• Unlisted formulation or manufacturing patents
• Patent applications that have not matured into enforceable rights

For a generic applicant, an abbreviated new drug application would need to address the approved drug’s product characteristics and any applicable listed patents through the relevant certification pathway. A Paragraph IV challenge would be commercially meaningful only if enforceable Orange Book patents cover the reference product and the challenger can establish a viable design or invalidity position.

The active-ingredient age makes a conventional composition-of-matter challenge less relevant. The more material risks concern dosage form, delivery device, combination formulation, and method-of-use coverage.

When does Mydcombi lose exclusivity?

Mydcombi received FDA approval in 2023. The product’s regulatory exclusivity period depends on the statutory basis assigned to the application, while patent expiry depends on the specific patents covering the formulation, device, and use. The approval date alone does not establish a single generic-entry date.

Exclusivity component	Relevance to Mydcombi
New chemical entity exclusivity	Unlikely to apply because both active ingredients are established
New formulation or new dosage-form exclusivity	Potentially relevant, depending on FDA regulatory classification
Orphan exclusivity	Not applicable to a broad diagnostic mydriasis indication
Pediatric exclusivity	Possible only if separately awarded
Orange Book patents	Must be assessed patent by patent
Device protection	May remain relevant after drug exclusivity ends
Trade-secret protection	Can continue without a fixed statutory expiry, subject to independent discovery

A generic entrant could reach the market after regulatory exclusivity expires if it can satisfy the FDA’s requirements and avoid or overcome valid listed patents. A non-infringing conventional drop formulation may avoid device claims but would not necessarily be substitutable at the pharmacy level if the reference product’s dosage form is protected or if the FDA requires a different application approach.

What commercial opportunities exist for Mydcombi?

Ophthalmology and optometry workflow

The most direct opportunity is procedural efficiency. Practices can use a fixed-dose combination instead of separately administering tropicamide and phenylephrine. The product may reduce:

• Number of administration steps
• Staff handling time
• Dropper-to-eye contact
• Medication waste
• Variability between operators
• Inventory requirements for separate mydriatic products

The economic case depends on whether the acquisition cost is offset by labor savings, reduced waste, faster patient throughput, and improved documentation.

High-volume diagnostic settings

Mydcombi is positioned for settings where dilation is repeated throughout the day:

• Retail eye-care clinics
• Optometry chains
• Ophthalmology practices
• Retinal screening programs
• Ambulatory surgical centers
• Hospital outpatient departments
• Mobile diagnostic programs

A metered spray may be attractive where staff administer thousands of doses annually and workflow standardization has measurable value.

Pediatric and sensitive-patient segments

Children and patients who resist drop administration may represent a targeted opportunity. Spray delivery can reduce the perceived invasiveness of administration, although commercial adoption still depends on ocular comfort, patient acceptance, and clinician confidence in adequate dilation.

The product should not be positioned as universally superior for every patient. Phenylephrine-containing products carry cardiovascular and systemic exposure considerations, and clinicians may continue to select alternative regimens for certain patients.

International expansion

Geographic expansion would require separate regulatory strategies because ophthalmic drug-device combinations face different requirements across the United States, Europe, Canada, Japan, and other markets. Key issues include:

• Device classification
• Multidose sterility requirements
• Preservative expectations
• Pediatric labeling
• Combination-product documentation
• Local patent rights
• Reimbursement and clinic purchasing systems

The excipient system is relatively familiar internationally, which may support regulatory portability. The device and human-factors package are likely to require greater adaptation.

How does Mydcombi compare with conventional mydriatic drops?

Factor	Mydcombi	Separate conventional drops
Active ingredients	Fixed combination	Often administered separately
Administration	Metered spray	Dropper-based
Dose variability	Potentially lower	Influenced by drop size and technique
Workflow	One product and fewer steps	Multiple products and timing steps
Preservative strategy	May support preservative-free positioning	Varies by product
Device dependence	High	Lower
Substitution risk	Limited by device and dosage form	Broad generic availability
Acquisition cost	Likely higher per unit	Generally lower
Main adoption barrier	Price and device familiarity	Established clinical habits

The product’s commercial hurdle is the gap between clinical convenience and procurement price. Practices may adopt Mydcombi when labor savings and throughput are visible. Payers and health systems may resist premium pricing if they view conventional tropicamide and phenylephrine drops as clinically interchangeable.

Which companies could challenge Mydcombi?

Potential competitors fall into three groups:

1. Generic ophthalmic manufacturers. Companies with established sterile ophthalmic manufacturing capabilities could develop conventional or fixed-dose alternatives.
2. Ophthalmic device companies. Device-focused competitors could pursue metered spray or low-volume delivery systems.
3. Branded ophthalmic companies. Established manufacturers could commercialize alternative fixed combinations, improved preservatives, or unit-dose presentations.

A direct generic challenge would face a different commercial problem from a therapeutic substitute. A conventional drop may be easier to manufacture but could lose the workflow and dosing advantages that support Mydcombi’s premium.

What are the main manufacturing and supply-chain barriers?

The active ingredients are commercially established. The harder manufacturing issues are likely to involve the integrated product system:

• Sterile compounding and filling
• Device assembly under controlled conditions
• Spray-dose calibration
• Container-closure integrity
• Priming and re-priming validation
• Extractables and leachables
• Long-term plume consistency
• Stability after opening
• Batch-to-batch actuator performance

The excipient system itself is not a major raw-material barrier. Boric acid, sodium borate, sodium chloride, and purified water are widely available. The strategic bottleneck is more likely to be qualified device supply and validated assembly capacity.

What revenue exposure and market risks affect Mydcombi?

Mydcombi’s revenue potential is tied to procedure volume rather than chronic daily dosing. That creates a concentrated customer base and a relatively direct sales model. The key commercial metrics are:

• Number of active prescribing practices
• Doses per practice per month
• Net price per administration
• Conversion from separate drops
• Reorder rates
• Gross-to-net deductions
• Payer and institutional coverage
• Device failure and replacement rates
• Sales-force cost per converted account

The principal risks are premium pricing, entrenched clinician habits, competing generic drops, supply interruptions, and limited reimbursement differentiation. The product is also exposed to regulatory scrutiny if device performance, dosing accuracy, sterility, or human-factors results do not remain consistent at commercial scale.

Key Takeaways

• Mydcombi combines tropicamide 1% and phenylephrine hydrochloride 2.5% in a metered ophthalmic spray.
• Its excipient strategy uses a buffered aqueous system with boric acid, sodium borate, sodium chloride, pH adjusters, and purified water.
• The commercial value of the formulation is closely linked to the Optejet delivery platform.
• Preservative-free or preservative-minimized positioning may support adoption in high-volume and ocular-surface-sensitive populations.
• The strongest intellectual-property barriers are likely to involve the device, fixed-dose formulation, administration method, and manufacturing process.
• Generic-entry risk is greater from formulation and device competition than from active-ingredient replication.
• The primary commercial opportunity is workflow improvement in ophthalmology and optometry practices.
• Premium pricing must be supported by lower administration variability, reduced waste, labor savings, or higher patient throughput.

FAQs

Can Mydcombi be reformulated as a preservative-containing product?

Yes, but adding a preservative could alter ocular tolerability, regulatory requirements, device compatibility, and commercial positioning. A preservative-containing version would need comparative stability, sterility, and ocular-safety support.

Could a generic manufacturer use the same tropicamide and phenylephrine concentrations?

Potentially, subject to FDA requirements and any enforceable patents covering the dosage form, formulation, device, or method of use. Matching the active concentrations alone would not necessarily reproduce the reference product.

Is the Mydcombi spray device more important than its excipients?

For differentiation, likely yes. The excipients support stability and tolerability, but the metered delivery system creates the principal workflow and dose-consistency proposition.

What is the best commercial channel for Mydcombi?

Specialty ophthalmology and optometry practices with high diagnostic volume are the most direct targets. Institutional outpatient clinics and retail eye-care networks may offer larger volume but usually impose greater pricing and formulary pressure.

Can Mydcombi’s excipient system support international registration?

The aqueous borate-buffered formulation uses globally familiar pharmaceutical excipients. International registration would still depend on local requirements for the spray device, sterility, multidose use, human factors, labeling, and combination-product classification.

References

1. Eyenovia, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

2. U.S. Food and Drug Administration. (2023a). FDA approves Mydcombi for pharmacologically induced mydriasis. Drugs@FDA.

3. U.S. Food and Drug Administration. (2023b). Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) prescribing information. Eyenovia, Inc.

4. U.S. Food and Drug Administration. (2023c). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

5. United States Pharmacopeia. (2023). General chapter <771>: Ophthalmic products. United States Pharmacopeial Convention.